Sales were driven by the launch of new indications globally. Keytruda sales are benefiting from a strong momentum in the indication of first-line lung cancer. 2019年前9个月,该药的销售额接近80亿美元,同比增长约63%。销售受到全球新适应症推出的推动。Keytruda的销售受益于一线肺癌适应症的强劲势头。
Keytruda is manufactured by Merck & Co. (known as MSD outside the United States and Canada), and their global headquarters are located in Rahway, New Jersey, USA. Keytruda is Merck's top-selling product, generating over $20 billion in annual sales. Other notable medications by Merck include...
Keytruda is also approved to treat melanoma in the US and has also been granted a priority review as a therapy for non-small cell lung cancer (NSCLC), with a decision on the latter indication due by October 2. While Keytruda was the first PD-1 inhibitor to reach the market in the US...
This becomes the third bladder cancer indication approval for Keytruda in the EU. Earlier this year, the European Society for Medical Oncology and the European Association of Urology issued guidelines recommending the Keytruda+Padcev combo as the preferred option for first-line treatment of advanced ...
In the trial of 886 bladder cancer patients who were eligible for cisplatin or carboplatin-containing chemotherapy, the Keytruda-Padcev combination reduced the risk of death by 53% over chemo, according to a late-breaking ESMO abstract.
and the street does not think that competitors will be able to meet this bar to commercially impact keytruda sales. with that said, the trial results could act as an overhang in the near-term until full results are released in 2020. keytruda is key to the bull thesis ...